Source: ClinicalTrials.gov
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
View on ClinicalTrials.govCitation record
- Study start
- 2024-10-23
- NCT number
- NCT06337318
- Phase
- Phase3
- Overall status
- Recruiting
- Study type
- Interventional
- Lead sponsor
- National Cancer Institute (NCI)
- Enrollment
- 600 participants
- Conditions
- Classic Follicular Lymphoma · Follicular Lymphoma With Unusual Cytological Features
- Interventions
- Biospecimen Collection (Procedure) · Computed Tomography (Procedure) · Mosunetuzumab (Biological) · Positron Emission Tomography (Procedure) · Rituximab (Biological) · Rituximab and Hyaluronidase Human (Biological)
- Last updated at source
- 23 Oct 2026
- Original source
- https://clinicaltrials.gov/study/NCT06337318
This page reproduces citation metadata only. Inclusion in the Avion Science research library does not imply endorsement and does not establish the safety, efficacy or intended use of any Avion Science compound. Refer to the original record for complete study information.